Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREASURE-CKD tirzepatide renal function study in obesity/overweight with chronic kidney disease
NL-OMON51386Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tirzepatide in chronic kidney disease (CKD), obesity, Overweight and 1 more, sponsored by Eli Lilly and Company. Primary endpoint: Kidney oxygenation. Started Jul 2023; status: recruiting.
02
Drugs
03
Conditions
chronic kidney disease (CKD)obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON51386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51386.